Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours

Phase 1

Completed

Conditions: Advanced Solid Malignancies
Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
Breast Cancer - ER+, HER2 -

Interventions: Drug: AZD8835
Drug: AZD8835 in combination with fulvestrant

First Posted Date: 2014-10-09

Last Posted Date: 2016-10-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 20

Registration Number: NCT02260661

Locations: 🇬🇧
Sarah Cannon Research Institute, United Kingdom, London, United Kingdom
🇬🇧
Research Site, Manchester, United Kingdom

A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA

Phase 3

Completed

Conditions: Asthma

Interventions: Biological: Benralizumab

First Posted Date: 2014-10-07

Last Posted Date: 2019-08-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 2133

Registration Number: NCT02258542

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance

Completed

Conditions: Type 2 Diabetes Mellitus

First Posted Date: 2014-09-30

Last Posted Date: 2020-03-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 3123

Registration Number: NCT02252224

Locations: 🇰🇷
Research Site, Wonju-si, Korea, Republic of

AZD8108 SAD/MAD in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: AZD8108
Drug: Placebo

First Posted Date: 2014-09-25

Last Posted Date: 2017-04-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 258

Registration Number: NCT02248818

Locations: 🇺🇸
Clinilabs, Inc., New York, New York, United States

AZD9496 First Time in Patients Ascending Dose Study

Phase 1

Completed

Conditions: ER+ HER2- Advanced Breast Cancer

Interventions: Drug: AZD9496

First Posted Date: 2014-09-25

Last Posted Date: 2019-06-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 45

Registration Number: NCT02248090

Locations: 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Sarah Cannon, Nashville, Tennessee, United States
🇬🇧
Research Site, Cambridge, United Kingdom

and more 2 locations

Non-interventional Study of Spirometry Use to Diagnose COPD (Chronic Obstructive Pulmonary Disease) and to Prescribe Treatment to COPD Patients in the Outpatient Institutions

Completed

Conditions: COPD

First Posted Date: 2014-09-25

Last Posted Date: 2016-04-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 4232

Registration Number: NCT02248909

Locations: 🇷🇺
Research Site, Stavropol, Nis-rru-xxx-2014/3, Russian Federation

An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease

Phase 2

Terminated

Conditions: Alzheimer´s Disease

Interventions: Drug: Placebo
Drug: Lanabecestat

First Posted Date: 2014-09-22

Last Posted Date: 2019-12-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 2218

Registration Number: NCT02245737

Locations: 🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇨🇦
Q&T Research Sherbrooke Inc, Sherbrooke, Quebec, Canada
🇺🇸
Banner Sun Health Research Institute, Sun City, Arizona, United States

and more 246 locations

24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Saxagliptin
Drug: Acarbose

First Posted Date: 2014-09-17

Last Posted Date: 2017-04-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 689

Registration Number: NCT02243176

Locations: 🇨🇳
Research Site, Shanghai, China

Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis

Completed

Conditions: Plaque Psoriasis

Interventions: Other: NIS

First Posted Date: 2014-09-15

Last Posted Date: 2017-08-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 899

Registration Number: NCT02239666

Locations: 🇬🇧
Research Site, Wolverhampton, United Kingdom

A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease COPD

Interventions: Drug: AZD7624 1.0 mg
Drug: Placebo

First Posted Date: 2014-09-12

Last Posted Date: 2018-05-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 213

Registration Number: NCT02238483

Locations: 🇿🇦
Research Site, Parktown West, South Africa

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy